A. Berggren

Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.

M. Karlsson, A. Berggren, 2009, Clinical therapeutics.

The direct and indirect costs of opioid-induced constipation.

C. Hjortsberg, F. Hjalte, H. Bergendahl, 2010, Journal of pain and symptom management.

Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study

B. Augustini, J. Karlsson, A. Söderström, 2014, Current medical research and opinion.

Pharmacokinetics of transdermal buprenorphine patch in the elderly

N. Al-Tawil, I. Odar‐Cederlöf, J. Persson, 2012, European Journal of Clinical Pharmacology.

Asthma control in patients on fixed dose combination evaluated with mannitol challenge test.

L. Bjermer, K. Romberg, A. Berggren, 2014, Respiratory medicine.

Response to the Letter to the Editor by Dr. Srinivas on the recent publication of Al-Tawil et al. on the pharmacokinetics of transdermal buprenorphine patch in the elderly

A. Berggren, Helen E. Johnson, 2013, European Journal of Clinical Pharmacology.